Tectonic Therapeutic, Inc.
$ 20.98
3.76%
04 Dec - close price
- Market Cap 392,668,000 USD
- Current Price $ 20.98
- High / Low $ 21.50 / 19.56
- Stock P/E N/A
- Book Value 14.30
- EPS -2.69
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -0.32 %
- 52 Week High 61.07
- 52 Week Low 13.70
About
Tectonic Therapeutic, Inc. is a biopharmaceutical innovator headquartered in Watertown, Massachusetts, specializing in the discovery and development of antibody-based therapies that target G-protein-coupled receptors (GPCRs), integral to numerous disease pathways. The company is dedicated to addressing significant unmet medical needs by developing novel treatment options for patients who have not responded well to current therapies. With a robust research and development pipeline, Tectonic is strategically positioned to lead advancements in biologic drugs, aiming to make impactful contributions to the therapeutic landscape.
Analyst Target Price
$78.71
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-14 | 2025-05-07 | 2025-03-12 | 2024-11-07 | 2024-08-14 | 2024-05-09 | 2024-03-20 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-23 |
| Reported EPS | -1.02 | -1.07 | -0.93 | -0.8364 | -1.2 | -4.34 | -1.8 | -0.5 | -0.48 | 1.52 | -0.57 | -0.57 |
| Estimated EPS | -0.13 | -1.32 | -1.0925 | -1.3867 | -0.84 | -1.3 | -0.36 | -0.43 | -0.355 | -0.5409 | -0.55 | -0.4929 |
| Surprise | -0.89 | 0.25 | 0.1625 | 0.5503 | -0.36 | -3.04 | -1.44 | -0.07 | -0.125 | 2.0609 | -0.02 | -0.0771 |
| Surprise Percentage | -684.6154% | 18.9394% | 14.8741% | 39.6841% | -42.8571% | -233.8462% | -400% | -16.2791% | -35.2113% | 381.0131% | -3.6364% | -15.6421% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: TECX
2025-10-17 11:30:00
Prelude Therapeutics has announced the appointment of Katina Dorton, J.D., MBA, to its Board of Directors, effective October 17, 2025. Dorton brings over 30 years of experience in healthcare and life sciences, including executive financial leadership and investment banking expertise. She will succeed Mardi C. Dier as Audit Committee Chair, who is resigning from the board.
2024-07-12 00:00:00
Tectonic Therapeutic, a Watertown biotech, decided to pursue a reverse merger instead of a Series B funding round. The CEO discusses the decision to merge with Avrobio, highlighting an unexpected opportunity that arose during their search for new funding. This move comes amidst a changing biotech environment.
2024-06-21 00:00:00
Tectonic Therapeutic has completed a reverse merger with Avrobio and begun trading on Nasdaq under the ticker 'TECX,' simultaneously raising $130.7 million in a private placement. The new company, with $181 million in cash reserves, is focused on its lead asset TX000045 (TX45) for group 2 pulmonary hypertension and plans clinical trials for a hereditary haemorrhagic telangiectasia (HHT) programme. Avrobio's stockholders now own approximately 24.8% of the combined entity, while Tectonic shareholders hold 75.2%.
2023-07-12 15:46:31
Avrobio Inc., a clinical-stage gene therapy company, has announced it will halt further development of its programs and explore strategic alternatives to maximize shareholder value. These alternatives could include an acquisition, merger, business combination, or other transaction. The company recently sold its cystinosis gene therapy program for $87.5 million.
2023-07-12 15:46:31
Avrobio, a gene therapy developer, announced it will cease further development of its experimental medicines and explore alternative business options, including a sale. This shift will result in a 50% workforce reduction, with remaining employees focusing on winding down research and fulfilling a recent deal with Novartis. The decision marks a retreat for the seven-year-old company, whose market value has declined significantly since its 2018 IPO, especially after disappointing clinical trial results for its most advanced gene therapy last year.
2023-05-22 15:46:31
AVROBIO, Inc. announced an agreement to sell its investigational cystinosis gene therapy program to Novartis for $87.5 million in cash. This transaction is expected to extend AVROBIO's cash runway into Q4 2024 and allows the company to focus on its remaining pipeline for Gaucher disease, Hunter syndrome, and Pompe disease. The deal includes the sale of assets related to the program and a license for AVROBIO's gene therapy platform for use in cystinosis by Novartis.
